Savient Pharmaceuticals, Inc. ( SVNT ) recently
entered into an agreement with Swedish Company Sobi for the
co-promotion of Kineret (anakinra) in the US.
Kineret is approved for the reduction in signs and symptoms
along with slowing the progression of structural damage in patients
(18 years of age or older) suffering from moderately-to-severely
active rheumatoid arthritis.
The patients have failed one or more disease modifying
antirheumatic drugs (DMARDs).
The label of Kineret was expanded in Jan 2013 when the US Food
and Drug Administration (FDA) approved the drug for the treatment
of children and adults suffering from neonatal-onset multisystem
inflammatory disease (NOMID). NOMID is a severe form of
Cryopyrin-Associated Periodic Syndromes (CAPS).
The agreement provides Savient the exclusive right to co-promote
Kineret with Sobi in the US. Savient will market and promote
Kineret from Apr 1, 2013.
Savient believes that Kineret complements the key focus of the
company as it works to build upon its existing relationships with
rheumatologists and patients while marketing its lead product,
Krystexxa is approved in the US for the treatment of refractory
chronic gout. Meanwhile, Savient also received marketing
authorization for Krystexxa from the EC.
Savient gained approval from the EC for the treatment of severe
debilitating chronic tophaceous gout in adults with erosive joint
These patients failed to normalize serum uric acid with xanthine
oxidase inhibitors at the highest dose.
Currently, Savient Pharmaceuticals carries a Zacks Rank #3
(Hold). Pharma stocks that look better-placed include Array
Biopharma ( ARRY ), Agenus
Inc ( AGEN
) and Alkermes ( ALKS ), all three
carrying a Zacks Rank #2 (Buy).AGENUS INC (AGEN): Free Stock Analysis ReportALKERMES INC (ALKS): Free Stock Analysis ReportARRAY BIOPHARMA (ARRY): Free Stock Analysis
ReportSAVIENT PHARM (SVNT): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment